|
2025-03-31 |
2025-03-28 |
VP
Vente planifiée
|
Summy Amy B.
EVP, Chief Marketing Officer
Dirigeant
|
758
-12.5%
231,67
175 606 USD
|
758
-12.5%
|
231,67
|
175 606 USD
|
|
|
2025-03-31 |
2025-03-28 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Dirigeant
|
2 635
-34.7%
231,67
610 450 USD
|
2 635
-34.7%
|
231,67
|
610 450 USD
|
|
|
2025-03-07 |
2025-03-05 |
V
Vente
|
ANDERSON KERRII B
Administrateur non-exécutif
|
500
-3.7%
255,63
127 817 USD
|
500
-3.7%
|
255,63
|
127 817 USD
|
|
|
2025-03-04 |
2025-02-28 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Dirigeant
|
5 339
-51.8%
249,23
1 330 639 USD
|
5 339
-51.8%
|
249,23
|
1 330 639 USD
|
|
|
2025-02-27 |
2025-02-25 |
V
Vente
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
1 314
-37.7%
251,30
330 208 USD
|
1 314
-37.7%
|
251,30
|
330 208 USD
|
|
|
2025-02-26 |
2025-02-24 |
VP
Vente planifiée
|
Summy Amy B.
EVP, Chief Marketing Officer
Dirigeant
|
226
-4.7%
250,40
56 590 USD
|
226
-4.7%
|
250,40
|
56 590 USD
|
|
|
2025-02-20 |
2025-02-18 |
V
Vente
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Dirigeant
|
1 413
-41.5%
246,10
347 739 USD
|
1 413
-41.5%
|
246,10
|
347 739 USD
|
|
|
2025-02-13 |
2025-02-11 |
VP
Vente planifiée
|
Schechter Adam H
President & CEO
Administrateur exécutif
|
6 121
-6.6%
244,62
1 497 319 USD
|
6 121
-6.6%
|
244,62
|
1 497 319 USD
|
|
|
2025-01-08 |
2025-01-07 |
VP
Vente planifiée
|
ANDERSON KERRII B
Administrateur non-exécutif
|
1 000
-7.3%
235,00
235 000 USD
|
1 000
-7.3%
|
235,00
|
235 000 USD
|
|
|
2024-12-04 |
2024-12-02 |
V
Vente
|
EISENBERG GLENN A
Executive Vice President
Dirigeant
|
11 711
-27.2%
240,43
2 815 651 USD
|
11 711
-27.2%
|
240,43
|
2 815 651 USD
|
|
|
2024-12-04 |
2024-12-02 |
V
Vente
|
Gilliland Dwight Gary
Administrateur non-exécutif
|
1 000
-11.5%
241,00
241 000 USD
|
1 000
-11.5%
|
241,00
|
241 000 USD
|
|
|
2024-11-26 |
2024-11-22 |
V
Vente
|
Summy Amy B.
EVP, Chief Marketing Officer
Dirigeant
|
3 672
-46.0%
238,91
877 142 USD
|
3 672
-46.0%
|
238,91
|
877 142 USD
|
|
|
2024-11-25 |
2024-11-21 |
V
Vente
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
1 000
-27.2%
239,42
239 419 USD
|
1 000
-27.2%
|
239,42
|
239 419 USD
|
|
|
2024-11-13 |
2024-11-11 |
VP
Vente planifiée
|
Schechter Adam H
President & CEO
Administrateur exécutif
|
6 189
-6.6%
243,47
1 506 836 USD
|
6 189
-6.6%
|
243,47
|
1 506 836 USD
|
|
|
2024-10-25 |
2024-10-24 |
VP
Vente planifiée
|
ANDERSON KERRII B
Administrateur non-exécutif
|
1 000
-6.8%
230,00
230 000 USD
|
1 000
-6.8%
|
230,00
|
230 000 USD
|
|
|
2024-08-21 |
2024-08-19 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
2 000
-35.3%
227,05
454 100 USD
|
2 000
-35.3%
|
227,05
|
454 100 USD
|
|
|
2024-08-19 |
2024-08-15 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
9 071
-22.5%
224,55
2 036 882 USD
|
9 071
-22.5%
|
224,55
|
2 036 882 USD
|
|
|
2024-08-19 |
2024-08-15 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
2 950
-6.8%
223,62
659 670 USD
|
2 950
-6.8%
|
223,62
|
659 670 USD
|
|
|
2024-08-19 |
2024-08-15 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
2 979
-6.4%
222,65
663 273 USD
|
2 979
-6.4%
|
222,65
|
663 273 USD
|
|
|
2024-08-09 |
2024-08-08 |
VP
Vente planifiée
|
ANDERSON KERRII B
Administrateur non-exécutif
|
586
-3.8%
225,00
131 850 USD
|
586
-3.8%
|
225,00
|
131 850 USD
|
|
|
2024-08-09 |
2024-08-07 |
VP
Vente planifiée
|
ANDERSON KERRII B
Administrateur non-exécutif
|
414
-2.6%
225,00
93 150 USD
|
414
-2.6%
|
225,00
|
93 150 USD
|
|
|
2024-08-07 |
2024-08-05 |
V
Vente
|
BERBERIAN LANCE
EVP, CIO & CTO
Dirigeant
|
9 848
-38.2%
228,95
2 254 685 USD
|
9 848
-38.2%
|
228,95
|
2 254 685 USD
|
|
|
2024-08-07 |
2024-08-05 |
V
Vente
|
BERBERIAN LANCE
EVP, CIO & CTO
Dirigeant
|
2 245
-8.0%
229,79
515 867 USD
|
2 245
-8.0%
|
229,79
|
515 867 USD
|
|
|
2024-05-16 |
2024-05-14 |
V
Vente
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
200
-3.4%
210,84
42 167 USD
|
200
-3.4%
|
210,84
|
42 167 USD
|
|
|
2024-05-16 |
2024-05-14 |
V
Vente
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
1 800
-23.6%
210,83
379 488 USD
|
1 800
-23.6%
|
210,83
|
379 488 USD
|
|
|
2024-05-02 |
2024-05-02 |
V
Vente
|
ANDERSON KERRII B
Administrateur non-exécutif
|
250
-1.6%
200,10
50 025 USD
|
250
-1.6%
|
200,10
|
50 025 USD
|
|
|
2024-05-02 |
2024-04-30 |
V
Vente
|
ANDERSON KERRII B
Administrateur non-exécutif
|
250
-1.5%
204,14
51 034 USD
|
250
-1.5%
|
204,14
|
51 034 USD
|
|
|
2024-05-01 |
2024-04-29 |
V
Vente
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Dirigeant
|
2 439
-53.9%
204,33
498 358 USD
|
2 439
-53.9%
|
204,33
|
498 358 USD
|
|
|
2024-04-03 |
2024-04-01 |
VP
Vente planifiée
|
Summy Amy B.
EVP, Chief Marketing Officer
Dirigeant
|
3 500
-46.8%
217,29
760 515 USD
|
3 500
-46.8%
|
217,29
|
760 515 USD
|
|
|
2024-04-03 |
2024-04-01 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Dirigeant
|
6 477
-56.3%
217,29
1 407 387 USD
|
6 477
-56.3%
|
217,29
|
1 407 387 USD
|
|
|
2024-03-29 |
2024-03-28 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
3 553
-31.8%
216,74
770 077 USD
|
3 553
-31.8%
|
216,74
|
770 077 USD
|
|
|
2024-03-11 |
2024-03-07 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Dirigeant
|
5 048
-50.1%
218,45
1 102 736 USD
|
5 048
-50.1%
|
218,45
|
1 102 736 USD
|
|
|
2024-03-11 |
2024-03-07 |
VP
Vente planifiée
|
Summy Amy B.
EVP, Chief Marketing Officer
Dirigeant
|
227
-5.6%
218,45
49 588 USD
|
227
-5.6%
|
218,45
|
49 588 USD
|
|
|
2024-02-22 |
2024-02-21 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
1 553
-6.2%
217,98
338 529 USD
|
1 553
-6.2%
|
217,98
|
338 529 USD
|
|
|
2024-02-22 |
2024-02-21 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
6 665
-21.0%
217,52
1 449 774 USD
|
6 665
-21.0%
|
217,52
|
1 449 774 USD
|
|
|
2024-02-22 |
2024-02-21 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
7 907
-19.9%
215,68
1 705 349 USD
|
7 907
-19.9%
|
215,68
|
1 705 349 USD
|
|
|
2024-02-22 |
2024-02-21 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
18 379
-31.6%
215,37
3 958 214 USD
|
18 379
-31.6%
|
215,37
|
3 958 214 USD
|
|
|
2024-02-22 |
2024-02-21 |
V
Vente
|
DiVincenzo Jonathan P.
EVP, Pres, Central Labs & Intl
Dirigeant
|
500
-12.8%
215,49
107 745 USD
|
500
-12.8%
|
215,49
|
107 745 USD
|
|
|
2024-02-15 |
2024-02-13 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
237
-3.0%
226,45
53 669 USD
|
237
-3.0%
|
226,45
|
53 669 USD
|
|
|
2024-02-09 |
2024-02-08 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
259
-3.3%
222,06
57 514 USD
|
259
-3.3%
|
222,06
|
57 514 USD
|
|
|
2024-02-06 |
2024-02-05 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
193
-2.5%
220,57
42 570 USD
|
193
-2.5%
|
220,57
|
42 570 USD
|
|
|
2023-11-20 |
2023-11-16 |
V
Vente
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Dirigeant
|
1 384
-39.9%
210,71
291 627 USD
|
1 384
-39.9%
|
210,71
|
291 627 USD
|
|
|
2023-08-10 |
2023-08-08 |
V
Vente
|
ANDERSON KERRII B
Administrateur non-exécutif
|
5 000
-24.7%
211,57
1 057 833 USD
|
5 000
-24.7%
|
211,57
|
1 057 833 USD
|
|
|
2023-07-03 |
2023-06-29 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
212
-2.7%
240,00
50 880 USD
|
212
-2.7%
|
240,00
|
50 880 USD
|
|
|
2023-05-23 |
2023-05-19 |
V
Vente
|
Kirchgraber Paul R
CEO, Covance Drug Development
Dirigeant
|
4 300
-24.9%
216,91
932 707 USD
|
4 300
-24.9%
|
216,91
|
932 707 USD
|
|
|
2023-05-22 |
2023-05-18 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, Pres Diagnostics & COO
Dirigeant
|
1 500
-18.3%
216,77
325 155 USD
|
1 500
-18.3%
|
216,77
|
325 155 USD
|
|
|
2023-04-03 |
2023-03-31 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Dirigeant
|
3 897
-36.8%
225,81
879 982 USD
|
3 897
-36.8%
|
225,81
|
879 982 USD
|
|
|
2023-02-23 |
2023-02-21 |
V
Vente
|
Kirchgraber Paul R
CEO, Covance Drug Development
Dirigeant
|
8 000
-46.9%
250,58
2 004 675 USD
|
8 000
-46.9%
|
250,58
|
2 004 675 USD
|
|
|
2023-02-16 |
2023-02-14 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Dirigeant
|
309
-4.4%
247,63
76 518 USD
|
309
-4.4%
|
247,63
|
76 518 USD
|
|
|
2023-02-09 |
2023-02-07 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
219
-3.9%
243,01
53 219 USD
|
219
-3.9%
|
243,01
|
53 219 USD
|
|
|
2023-02-09 |
2023-02-07 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Dirigeant
|
409
-5.8%
243,01
99 391 USD
|
409
-5.8%
|
243,01
|
99 391 USD
|
|
|
2023-02-06 |
2023-02-03 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Dirigeant
|
324
-4.6%
253,90
82 264 USD
|
324
-4.6%
|
253,90
|
82 264 USD
|
|
|
2023-02-06 |
2023-02-03 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
173
-3.1%
253,90
43 925 USD
|
173
-3.1%
|
253,90
|
43 925 USD
|
|
|
2022-11-10 |
2022-11-08 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Dirigeant
|
1 116
-14.3%
232,67
259 660 USD
|
1 116
-14.3%
|
232,67
|
259 660 USD
|
|
|
2022-09-28 |
2022-09-26 |
VP
Vente planifiée
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
2 830
-9.4%
211,86
599 573 USD
|
2 830
-9.4%
|
211,86
|
599 573 USD
|
|
|
2022-09-28 |
2022-09-26 |
VP
Vente planifiée
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
11 699
-28.1%
211,13
2 470 064 USD
|
11 699
-28.1%
|
211,13
|
2 470 064 USD
|
|
|
2022-09-28 |
2022-09-26 |
VP
Vente planifiée
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
4 844
-10.4%
210,21
1 018 242 USD
|
4 844
-10.4%
|
210,21
|
1 018 242 USD
|
|
|
2022-09-28 |
2022-09-26 |
VP
Vente planifiée
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
5 627
-10.8%
209,29
1 177 697 USD
|
5 627
-10.8%
|
209,29
|
1 177 697 USD
|
|
|
2022-09-13 |
2022-09-07 |
AP
Achat planifié
|
Caveney Brian J
EVP, President of Diagnostics
Dirigeant
|
44
+0.3%
231,20
10 251 USD
|
44
+0.3%
|
231,20
|
10 251 USD
|
|
|
2022-08-05 |
2022-08-03 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
1 500
-2.8%
254,88
382 319 USD
|
1 500
-2.8%
|
254,88
|
382 319 USD
|
|
|
2022-08-05 |
2022-08-03 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
19 338
-26.5%
254,26
4 916 861 USD
|
19 338
-26.5%
|
254,26
|
4 916 861 USD
|
|
|
2022-08-05 |
2022-08-03 |
V
Vente
|
EISENBERG GLENN A
Chief Financial Officer, EVP
Dirigeant
|
11 262
-13.4%
253,27
2 852 270 USD
|
11 262
-13.4%
|
253,27
|
2 852 270 USD
|
|
|
2022-08-03 |
2022-08-01 |
V
Vente
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Dirigeant
|
10
-0.5%
258,71
2 587 USD
|
10
-0.5%
|
258,71
|
2 587 USD
|
|
|
2022-08-03 |
2022-08-01 |
V
Vente
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Dirigeant
|
757
-28.5%
258,60
195 760 USD
|
757
-28.5%
|
258,60
|
195 760 USD
|
|
|
2022-08-03 |
2022-08-01 |
V
Vente
|
Wilkinson Peter J
SVP, Chief Accounting Officer
Dirigeant
|
1 809
-48.9%
258,31
467 287 USD
|
1 809
-48.9%
|
258,31
|
467 287 USD
|
|
|
2022-06-14 |
2022-06-07 |
A
Achat
|
Caveney Brian J
EVP, President of Diagnostics
Dirigeant
|
42
+0.3%
242,19
10 174 USD
|
42
+0.3%
|
242,19
|
10 174 USD
|
|
|
2022-03-29 |
2022-03-25 |
VP
Vente planifiée
|
Williams R Sanders
Administrateur non-exécutif
|
572
-8.2%
272,98
156 145 USD
|
572
-8.2%
|
272,98
|
156 145 USD
|
|
|
2022-03-14 |
2022-03-10 |
V
Vente
|
Summy Amy B.
EVP, Chief Marketing Officer
Dirigeant
|
249
-49.9%
262,21
65 290 USD
|
249
-49.9%
|
262,21
|
65 290 USD
|
|
|
2022-02-18 |
2022-02-16 |
A
Achat
|
NEUPERT PETER M
Administrateur non-exécutif
|
600
+6.2%
264,57
158 742 USD
|
600
+6.2%
|
264,57
|
158 742 USD
|
|
|
2022-02-18 |
2022-02-16 |
A
Achat
|
NEUPERT PETER M
Administrateur non-exécutif
|
1 600
+19.9%
263,98
422 368 USD
|
1 600
+19.9%
|
263,98
|
422 368 USD
|
|
|
2022-02-18 |
2022-02-16 |
A
Achat
|
NEUPERT PETER M
Administrateur non-exécutif
|
1 300
+19.2%
262,85
341 705 USD
|
1 300
+19.2%
|
262,85
|
341 705 USD
|
|
|
2022-02-17 |
2022-02-15 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Dirigeant
|
207
-3.0%
273,98
56 714 USD
|
207
-3.0%
|
273,98
|
56 714 USD
|
|
|
2022-02-17 |
2022-02-15 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
207
-3.8%
273,98
56 714 USD
|
207
-3.8%
|
273,98
|
56 714 USD
|
|
|
2022-02-08 |
2022-02-07 |
VP
Vente planifiée
|
Schroeder Mark S
EVP, President-Diagnostics Lab
Dirigeant
|
204
-3.0%
277,38
56 586 USD
|
204
-3.0%
|
277,38
|
56 586 USD
|
|
|
2022-02-08 |
2022-02-07 |
VP
Vente planifiée
|
van der Vaart Sandra D
EVP, Chief Legal Officer
Dirigeant
|
218
-4.0%
277,38
60 469 USD
|
218
-4.0%
|
277,38
|
60 469 USD
|
|
